A5058351187- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Blood Pressure and Hypertension Studies
- Cardiac pacing and defibrillation studies
- Atrial Fibrillation Management and Outcomes
- Congenital Heart Disease Studies
- Hemodynamic Monitoring and Therapy
- Diabetes Treatment and Management
- Cardiovascular Syncope and Autonomic Disorders
- Cardiac Arrhythmias and Treatments
- Medical research and treatments
- Cardiac Valve Diseases and Treatments
- Pericarditis and Cardiac Tamponade
- Cardiac, Anesthesia and Surgical Outcomes
- Viral Infections and Immunology Research
- Vascular anomalies and interventions
- Hormonal Regulation and Hypertension
- Body Composition Measurement Techniques
- Cardiomyopathy and Myosin Studies
- Renal and Vascular Pathologies
- Congenital Anomalies and Fetal Surgery
- Central Venous Catheters and Hemodialysis
- Inflammasome and immune disorders
- Peripheral Artery Disease Management
- Nursing care and research
Universidad Alfonso X el Sabio
2025
Hospital Universitario Fundación Jiménez Díaz
2016-2025
Centro de Investigación en Red en Enfermedades Cardiovasculares
2024-2025
Complejo Hospitalario Universitario de Santiago
2024
Universidad Autónoma de Madrid
2016-2018
Hospital Universitario de La Princesa
2018
Hospital de Basurto
2007
University of the Basque Country
2007
Abstract Background and Aims Acute heart failure (AHF) promotes inflammatory activation, which is associated with worse outcomes. Colchicine has proven effective in other cardiovascular conditions characterized by but never been evaluated the setting of AHF. Methods This multicenter, randomized, double-blind placebo-controlled trial included patients AHF, requiring ≥40 mg intravenous furosemide, regardless their left ventricular ejection fraction (LVEF) inpatient or outpatient setting....
As evidenced by scintigraphy imaging, the prevalence of transthyretin (TTR) cardiac amyloidosis in heart failure patients with preserved ejection fraction (HFpEF) and left ventricular hypertrophy (LVH) ranges between 13% 19%. The natural evolution begins deposition amyloid material myocardium, LVH ensuing at later stages. With current imaging modalities, it is possible to detect TTR before hypertrophic stage. aim this study was determine HFpEF without LVH.The prospectively enrolled admitted...
Natriuretic peptides are established biomarkers related to the prognosis of heart failure. New have emerged in field cardiovascular disease. The prognostic value these failure with reduced left ventricular ejection fraction is not well-established. We conducted a prospective, single-centre study, including (July 2019 March 2023) 104 patients being consecutively admitted diagnosis acute decompensation. median follow-up was 23.5 months, during which 20 deaths (19.4%) and 21 readmissions for...
Abstract Aims Heart failure (HF) elicits a pro‐inflammatory state, which is associated with impaired clinical outcomes, but no anti‐inflammatory therapies have demonstrated benefit yet. Inflammatory pathways related the interleukin‐1 axis are overactivated during episodes of acute HF. Colchicine, an drug proven benefits in pericarditis and ischaemic heart disease, may target this inflammatory response. This study aims to assess efficacy colchicine HF patients. Methods COLICA multicentre,...
(1) Background: The validation of new lines therapy for the elderly is required due to progressive ageing world population and scarce evidence in patients with HF reduced ejection fraction (HFrEF). purpose our study analyze effect SGLT2 inhibitors (SGLT2i) this subgroup patients. (2) Methods: A single-center, real-world observational was performed. We consecutively enrolled all aged ≥ 75 years diagnosed HFrEF treatment SGLT2i, considered theoretical indications. (3) Results: total 364 were...
Background: Heart failure (HF) is a highly prevalent syndrome in elderly subjects. Currently, multiple drugs have shown clinical benefits patients with HF and reduced ejection fraction (HFrEF). However, evidence scarce (beyond 75 years old), even more so for the latest drugs, such as angiotensin receptor-neprilysin inhibitors (ARNIs). This study aims to evaluate use of ARNIs HFrEF. Methods: A prospective observational cohort was designed. Patients left ventricular systolic dysfunction...
We report the case of a 13-year-old boy who, previously in healthy condition, was admitted to hospital with an acute ischemia lower half trunk following slight traumatism. During surgical operation it noticed that embolized material corresponded hydatid vesicles. The patient died as result irreversible anaphylactic shock after operation. autopsy revealed presence cyst posterior wall left atrium which had ruptured into atrial cavity. immediate exeresis cardiac is suggested, when made up...
Abstract Aims Residual congestion at the time of hospital discharge is an important readmission risk factor, and its detection with physical examination usual diagnostic techniques have strong limitations in overweight obese patients. New tools like bioelectrical impedance analysis (BIA) could help to determine when euvolaemia reached. The aim this study was investigate usefulness BIA management heart failure (HF) Methods results Our a single‐centre, single‐blind, randomized controlled trial...
Heart failure (HF) with reduced left ventricle ejection fraction (LVEF) is an entity poor prognosis characterized by decompensations. Bioelectrical impedance analysis (BIA) used to assess volume overload (VO) and may be useful identify apparently stable HF outpatients at risk of decompensation. The aim this study analyse whether VO assessed BIA associated worsening heart (WHF) in LVEF (HFrEF).
Sodium-glucose cotransporter inhibitors (SGLT2i) have demonstrated a reduction in cardiovascular events diabetes and heart failure (HF). The mechanisms underlying this benefit are not well known data contradictory. purpose of study is to analyse the effect dapagliflozin on cardiac structure function patients with normal ejection fraction. Between October 2020 2021, we consecutively included 31 diabetic without prior history SGLT2i use. In all them, treatment was started. At inclusion during...
Clinical management of cardiac resynchronization therapy (CRT) non-responders is difficult, and their prognosis poor. The aim the present study was to evaluate whether treatment with sacubitril/valsartan can improve quality life (QoL) parameters in these patients.Thirty five CRT were included (75 ± 7 years, 28% females, mean left ventricular ejection fraction 28 8%, 54% non-ischemic cardiomyopathy) maximally optimized drug New York Heart Association class II-III. They all on...
OBJECTIVE To assess the role of beta-blockers (BB) in patients with chronic kidney disease (CKD) aged ≥ 75 years. METHODS AND RESULTS From January 2008 to July 2014, we included 390 consecutive years age ejection fraction ≤ 35% and glomerular filtration rate (GFR) 60 mL/min per 1.73 m2. We analyzed relationship between treatment BB mortality or cardiovascular events. The mean our population was 82.6 ± 4.1 Mean 27.9% 6.5%. GFR 60-45 m2 50.3% patients, 45-30 37.4%, < 30 m 2 12.3%. At...
Background: Self-care and empowerment promotion in patients with heart failure (HF) is essential for improving their prognosis, but there limited information concerning the patients' depth of knowledge about this pathology as well patient satisfaction within units (HFUs). Our objective was to assess both aspects a cohort regularly followed-up HFUs. Methods: A multicenter, observational study conducted consecutive followed 14 HFUs between June November 2023. It based on cross-sectional survey...
Heart failure (HF) remains a disease of increasing prevalence and morbidity. Validation new lines therapy in the elderly are required due to progressive ageing world's population scarce evidence patients with HF reduced ejection fraction (HFrEF). The purpose our study is analyse effect Angiotensin Receptor–Neprilysin Inhibitors (ARNI) this subgroup patients. We conducted single-centre, real-world observational study. consecutively enrolled all aged ≥75 years diagnosed HFrEF (defined as an...
SGLT-2 receptor inhibitors (SGLT-2i) have been shown to reduce cardiovascular mortality and hospitalisations for heart failure (HF) in patients with HF reduced ejection fraction (HFrEF) a nephroprotective role chronic kidney disease (CKD). However, the available evidence older than 75 years CKD is limited. We conducted retrospective, single-centre study including aged >75 diagnosed HFrEF (defined as <40%), (eGFR <60mL/min) an indication treatment SGLT-2i between November 2019 2022....
Natriuretic peptides are established biomarkers related to the prognosis of heart failure.New have emerged in area cardiovascular disease. The prognostic value these failure with reduced LVEF (HFrEF) is not well established.We conducted a prospective, single-centre study, including consecutively (July 2019 March 2023) 104 patients admitted diagnosis acute HFrEF decompensation.Median follow-up was 23.5 months, during which 20 deaths (19.4%) and 21 readmissions for (20.2%) were recorded....